ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/anti-TIM3-monoclonal-antibody
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/anti-TIM3-monoclonal-antibody
3
trial(s) found.
NCT06162572
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression (
SPLFIO-174
)
Cemiplimab
S095018
S095024
S095029
anti-CD73 monoclonal antibody
anti-NKG2A monoclonal antibody
anti-PD-1 monoclonal antibody
anti-TIM3 monoclonal antibody
cancer therapy
cancer therapy,CD73-targeting
cancer therapy,NKG2A-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,TIM3-targeting
immune checkpoint blockade
immune checkpoint blockade,CD73-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,TIM3-targeting
immuno-oncology therapy,CD73-targeting
immuno-oncology therapy,NKG2A-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,TIM3-targeting
+ anti-TIM3 monoclonal antibody
Non-small cell lung cancer
NSW
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3844 - Traralgon - Latrobe Regional Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
+ anti-TIM3 monoclonal antibody
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12621001265864
Haem
Phase 1 / Phase 2
Recruiting
AMLM26/T5- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - MBG453 OR MBG453 and Azacitidine (
AMLM26-T5
)
DNA methyltransferase inhibitor
anti-TIM3 monoclonal antibody
antimetabolite
Acute myeloid leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (2)
Enrolling by invitation (1)
Recruitment Country and State
NSW (3)
SA (3)
VIC (3)
QLD (2)
NZ (1)
WA (1)
Phase
Phase 1 / Phase 2 (2)
Phase 3 (1)
Trial Type
Advanced (2)
Haem (1)
Cancer Therapy Class
TIM3
100%
PD-1
67%
PD-1/PD-L1
67%
CD73
33%
NKG2A
33%
ERBB2
33%
HPK1
33%
KIT
33%
LAG3
33%
OX40
33%
PARP
33%
PDGFR
33%
RET
33%
TIGIT
33%
VEGF
33%
VEGFR
33%
VEGFR1
33%
VEGFR2
33%
VEGFR3
33%
DNA methyltransferase
33%
Facility
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
3168 - Clayton - Monash Medical Centre (2)
2640 - Albury - Border Medical Oncology Research Unit (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
2031 - Randwick - Prince of Wales Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
Cancer Type
Cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Solid tumour
Thoracic cancer
Acute myeloid leukaemia
Haematological malignancy
Leukaemia
Myeloid leukaemia
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy